Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
avicin d
- Development stage
- Unknown
- Lead developer
- Avicin Therapeutics
- Modality
- Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Avicin D is a natural triterpenoid saponin isolated from plants such as Archidendron ellipticum and Acacia victoriae. It has demonstrated anticancer and anti-inflammatory properties in preclinical studies. Mechanistically, Avicin D acts as a selective glucocorticoid receptor (GR) modulator and induces apoptosis in various tumor cell lines by downregulating phosphorylated STAT3 (p-STAT3), bcl-2, and survivin proteins. It also inhibits NF-κB activation in a GR-dependent manner and suppresses GRE-mediated gene expression. Preclinical data suggest potential therapeutic applications for cutaneous T-cell lymphoma (CTCL), Sézary syndrome, multiple myeloma, and other cancers[3][4][5][9].
- Other names
- Avicin Delliptoside e69451KN1ROUNII-69451KN1ROUNII69451KN1ROUNII 69451KN1RO197787-20-5
02
Targets
GR (Glucocorticoid receptor)STAT3 (Signal Transducer and Activator of Transcription 3)
Beyond the preview
Go deeper on avicin d.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on avicin d.